20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)

Over 15,000 dogs per year diagnosed with osteosarcoma

Company expects to submit U.S. Department of Agriculture meeting request to gain alignment on regulatory path towards conditional approval in the third quarter of 2026

OS Therapies reiterates plan to distribute OS Animal Health shares to shareholders

OS Animal Health plans crowdfunding to expand shareholder base to meet U.S. national exchange initial listing standards, with indications of interest now being received

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.